Related Experiment Video
Updated: Jun 3, 2026

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
Mild cognitive impairment: The dilemma
Charles Pinto1, Alka A Subramanyam
1Department of Psychiatry, TN Medical College and BYL Nair Hospital, Mumbai - 400008, India.
Abstract:
Memory complaints are ubiquitous in our aging population. Many older adults fear that today's forgetfulness will usher in tomorrow's dementia. Mild cognitive impairment (MCI) is considered by many as an intermediary stage for dementia. Though the nomenclature has been varied and extensive, the criteria by the American Academy of Neurology and the EADC have been helpful. Prevalence rates varying from 3% to as high as 59% with a conversion rate to dementia varying from 8 to 15% only increases the need for diagnostic tests and markers which are in the form of neuropsychological tests, neuroimaging and other biological markers.Medications indicated for treatment of mild to severe Alzheimer's Disease (AD) are offered to persons with MCI with a varying type of response which does not hold in the long run to newer strategies of exploring disease modifying drugs which hold a better promise. This benefit with management of risk factors like hypertension and diabetes coupled with non-pharmacological approaches like exercise and social networking has thrust upon us the necessity for coordinating our efforts to improve detection and management of MCI.
Insights
Mild cognitive impairment (MCI) affects many older adults, increasing dementia risk. Early detection and management, including risk factor control and new therapies, are crucial for better outcomes.
Area of Science:
- Neurology
- Geriatrics
- Cognitive Science
Background:
- Memory complaints are common in aging populations, raising concerns about progression to dementia.
- Mild cognitive impairment (MCI) is recognized as a potential precursor stage to dementia.
- Varied nomenclature and diagnostic criteria necessitate standardized approaches.
Purpose of the Study:
- To highlight the prevalence and conversion rates of MCI to dementia.
- To emphasize the need for improved diagnostic tools and biomarkers for MCI.
- To discuss current and emerging treatment strategies for MCI and Alzheimer's Disease.
Main Methods:
- Review of existing literature on MCI prevalence, diagnosis, and management.
- Analysis of diagnostic criteria from organizations like the American Academy of Neurology and EADC.
- Examination of treatment responses to Alzheimer's Disease medications and non-pharmacological interventions.
Main Results:
- MCI prevalence varies widely (3-59%), with 8-15% converting to dementia.
- Neuropsychological tests, neuroimaging, and biological markers are essential for MCI detection.
- Current Alzheimer's Disease medications show limited long-term efficacy in MCI, prompting research into disease-modifying drugs.
Conclusions:
- Coordinated efforts are needed to enhance the detection and management of MCI.
- Integrating risk factor management (hypertension, diabetes) and non-pharmacological approaches (exercise, social networking) is vital.
- Further research into disease-modifying drugs offers promise for future MCI and dementia treatment.
Related Concept Videos
Dementia l: Introduction
Cognitive Development During Adulthood
Dementia
The progression of dementia is generally gradual.
Alzheimer Disease l: Introduction
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Intellectual Disability

